ASX BRIEFS

Hosted by Andrew Musgrave

Business Investing

Website RSS feed

Episodes

257

Latest episode

Oct 2026

Language

EN-AU

About the show

Welcome to 'ASX BRIEFS,' the definitive podcast for enthusiasts, investors, and professionals keen on staying ahead of the curve in the Australian Stock Exchange (ASX). Hosted by Andrew Musgrave, 'ASX BRIEFS' delves deep into the heart of Australia's financial markets, bringing you insightful conversations with the minds shaping the future of investing down under. Each episode, join Andrew as he interviews a diverse lineup of fund managers, executives, and industry insiders, offering you a unique blend of expert analysis, strategic insights, and the latest trends affecting the ASX. Whether you're a seasoned investor or just starting out, 'ASX BRIEFS' is your go-to source for comprehensive updates and thought-provoking discussions designed to inform, inspire, and empower your investment journey. Tune in to 'ASX BRIEFS' and take the pulse of Australia's financial markets right at your fingertips.

Listen to episodes

60 recent

October 20, 202616 min

VECTUS BIOSYSTEMS LTD (ASX:VBS) - A Drug That May Reverse Lung Scarring

Send us Fan Mail ASX Investment Opportunity - Vectus Biosystems Ltd (ASX:VBS) Lung scarring that won’t stop, treatments that mostly slow the slide, and a median survival often measured in years, not decades, is why idiopathic pulmonary fibrosis (IPF) is one of the most urgent targets in respiratory medicine. We’re joined by Dr Tara Speranza, CEO and CTO of Vectus Biosystems, to explain why the company is putting VB0004 forward as its lead program and why the preclinical signals suggesting fibrosis reversal have caught the attention of clinicians and key opinion leaders. We talk through what “idiopathic” really means, how IPF differs from lung fibrosis caused by smoking, asbestos, or other environmental triggers, and why patients and families are still waiting for something that goes beyond slowing progression. Tara also shares the strategic logic behind leading with a rare disease indication, including the potential benefits of an orphan drug pathway and the practical reality that big heart and kidney fibrosis trials can be far more expensive and recruitment-heavy. On the regulatory front, we unpack the FDA pre-IND Type B meeting, what the agency’s engagement can tell you at this stage, and the specific clarity Vectus is seeking on preclinical coverage and CMC (chemistry, manufacturing and controls). We also cover why Cardinal Health Regulatory Services has been appointed as Vectus’ US agent, and how that expertise supports the step-by-step build towards an IND and US clinical trials. Finally, we look beyond the lead asset: a 1,000+ small molecule fibrosis library, how candidates are screened from in vitro assays into gold-standard animal models, and where AI-driven modelling could help pick the next winners faster. If you care about ASX biotech, pulmonary fibrosis treatment innovation, or how drugs actually move through the FDA pathway, this one’s for you. Subscribe, share the episode with a mate, and leave us a review so more people can find the conversation.

October 16, 202612 min

OVERWATCH TECHNOLOGIES LTD (ASX:OWL) - How Overwatch Turns Drones Into Maritime Intelligence

Send us Fan Mail ASX Investment Opportunity - Overwatch Technologies Ltd (ASX:OWL) Australia and the Indo-Pacific are dealing with a hard truth: our oceans are vast, threats move fast, and traditional maritime surveillance is expensive to scale. We sit down with Oscar Leslie, Managing Director and co-founder of Overwatch Technologies Limited, to dig into how modern maritime domain awareness can be built with autonomous systems, AI-enabled surveillance, and smart sensor networks that spot what matters before a navy has to launch its most costly assets. Oscar explains why Overwatch stays platform agnostic, choosing the best-value drones and uncrewed surface vessels, then fitting them with proprietary sensors to collect electro-optical imagery and radio frequency signals. We walk through the company’s “sense, capture, process, monetise” model, including how vessel fingerprinting and data fusion can identify suspicious behaviour such as ships that disable AIS. There’s also a deep dive into the strategic value of Overwatch’s exclusive regional licence for military-grade RF sensing technology from Europe-based Polis Tech, and how avoiding US ITAR restrictions can open doors for regional government customers. We also get practical about the numbers and the pathway: why early revenue leans on hardware sales, how contract liabilities work until delivery is completed, and what changes when the business shifts to maritime surveillance as a service with stronger margins and multi-year customer stickiness. Oscar closes with milestones to watch over the next 6 to 12 months, from converting early traction into service contracts to laying foundations for longer-term data monetisation, plus why building sovereign Australian capability matters for allied cooperation frameworks like AUKUS and Five Eyes. Subscribe, share this with a mate who follows defence tech, and leave a review, what part of this scaling story do you want us to unpack next?

October 15, 20268 min

PIONEER CREDIT LTD (ASX:PNC) - Ethical Debt Recovery On The ASX

Send us Fan Mail ASX Investment Opportunity - Pioneer Credit Ltd (ASX:PNC) A 245% jump in statutory profit doesn’t happen by accident, especially in a part of finance most people only hear about when things go wrong. We’re joined by Keith John, Managing Director of Pioneer Credit Limited, to explain how an ASX-listed debt purchaser can grow fast while keeping customer outcomes and compliance front and centre. If you’ve ever wondered how purchased debt portfolios work, why banks sell non-performing loans, and what “ethical recovery” looks like in practice, this chat lays it out clearly. We walk through the key tailwinds behind Pioneer Credit’s FY26 result, from a surprisingly tight competitive field to the real-world behaviour of Australian consumers under interest rate and cost of living pressure. Keith also explains how being aligned with bank vendors (and not competing by writing new loans) can influence deal flow, pricing, and long-term relationships. Along the way, we discuss the scale of the current receivables book, what “under arrangement” really means, and why disciplined collections matter as much as headline NPAT. Then we get practical on capital structure: debt facility repricing, lower funding margins over BBSW, reduced leverage since COVID, and how a stronger balance sheet can support ongoing portfolio investment and a pathway back to dividends. We also touch on the PwC litigation and what to watch in the next 12 months, before closing on the milestones needed to hit FY27 cash collections guidance and the FY29 NPAT target. If you value clear ASX insights, subscribe, share this with a mate, and leave a review. What’s the bigger signal for you here: cheaper funding, portfolio buying pace, or cash collections?

October 13, 202612 min

CYCLOPHARM LTD (ASX:CYC) - Why Lung Imaging Guidelines Are Shifting Towards Technegas

Send us Fan Mail ASX Investment Opportunity - Cyclopharm Ltd (ASX:CYC) China’s leading medical bodies have now named Technegas the preferred ventilation agent for pulmonary embolism imaging, and that single line has big implications. We sit down with Cyclopharm Managing Director and CEO James McBrayer to unpack what’s driving the sudden global alignment of clinical guidelines across the US, Europe, Australia and New Zealand, and China and why it’s rare for medical guidance to call out a brand by name. We start with the fundamentals of Technegas lung imaging: how a few breaths can produce a clear map of pulmonary ventilation, and why image quality and stability matter even more as hospitals move to SPECT and 3D workflows. James also walks us through the patient safety angle, including guideline commentary on radiation dose versus CT pulmonary angiography, and why evidence based practice is pushing clinicians towards a consistent “standard of care”. From there, we dig into the business and ASX investor lens: the razor blade model of recurring consumable revenue, the acceleration in US sites after FDA approval, and how network contracts and reference hospitals drive scalable rollout. We also cover delayed sites tied to funding and facility timelines, plus the “Beyond PE” growth strategy that includes CTEPH, COPD, asthma, and pre and post surgical lung assessment. Finally, we look at how AI is reshaping lung imaging by combining CT anatomy with functional ventilation data, turning scans into measurable regional lung performance that clinicians can track over time. Subscribe for more ASX Briefs, share this episode with a mate, and leave a review with your biggest takeaway.

October 6, 20265 min

MYECO GROUP LTD (ASX:MCO) - MyEco’s Three Growth Engines

Send us Fan Mail Council contracts don’t sound exciting until you realise they can change how millions of Australians deal with food waste every week. On this podcast, Marie de Perthuis, CEO of MyEco Group Limited, unpacks a refined growth strategy built to scale: council supply, national retail distribution, and product range expansion. If you follow ASX-listed sustainability businesses, this is a grounded look at how a “better for the planet” product becomes a repeat-purchase staple with real distribution behind it. We talk through why each additional council win matters for compostable kitchen caddy liners and compostable waste products, and how that reach into households strengthens MyEco’s position in the organics market. Marie also explains the commercial logic: consistent council demand can build a platform that supports broader category growth, especially as councils and communities push for cleaner FOGO outcomes. Then we shift to shelves and store counts. With new ranging agreements across Foodland, Ritchies IGA, and Cornett’s IGA, we dig into what independent grocery distribution can do for brand visibility and long-term scale. Marie shares how retail expansion creates room to introduce additional sustainable household products over time, backed by FY26 Australian retail sales growth. Finally, we explore product range expansion into the Eco-Home category, including FSC Chain of Custody certification and a 100% bamboo tissue and paper towel range, plus the planned digital launch in Q3 FY27. We also cover capital management, including the share purchase plan and how funding supports inventory, retail rollouts, and further council and online growth. If you want a clear view of where the next 12 months of milestones could come from, hit play, subscribe, share this with a mate, and leave us a review with your take on which growth engine matters most.

September 24, 20268 min

FORTUNA METALS LTD (ASX:FUN) - What Happens When Critical Minerals Meet A Supply Crunch

Send us Fan Mail ASX Investment Opportunity - Fortuna Metals Ltd (ASX:FUN) A world-scale rutile story doesn’t usually appear overnight, but Mkanda has moved at a pace that’s hard to ignore. We sit down with Tom Langley, CEO of Fortuna Metals, to trace how the Mkanda Rutile Graphite Project in Malawi jumped from acquisition to an inferred resource that ranks among the top contained rutile deposits globally, and why that speed is possible when mineralisation starts at surface and stays open. We break down what makes Mkanda geologically different from many mineral sands style projects. Tom explains how high-grade metamorphism in Malawi upgrades titanium-bearing minerals so the deposit skews heavily toward rutile, then how weathering helps reconcentrate minerals near surface. We also get into metallurgy and why it matters: bulk sample test work points to a high-purity rutile product at 96% plus TiO2 with low impurities, the sort of detail that pigment, welding and titanium metal producers care about when they think about specifications, penalties and reliable supply. The conversation widens to the optionality that could change the economics over time. Alongside rutile, Mkanda carries graphite and shows elevated heavy rare earths like dysprosium, terbium and yttrium, plus potential zircon and monazite. We talk funding and strategy too, including why a Silicon Valley based cornerstone investor is part of the register, and what Malawi’s rail access and the route to the deep-water port at Nacala could mean for logistics. We finish with the macro picture: tightening natural rutile supply, growing demand signals across industrial end uses, and the “blue sky” narrative around titanium and humanoid robotics. If you’re tracking ASX critical minerals, titanium dioxide feedstocks, or emerging African mining jurisdictions, this is a practical update with clear near-term catalysts. Subscribe, share the episode with a mate who follows resources, and leave us a review.

September 21, 202619 min

QBIOTICS LTD - QBiotics Cancer Injection Shows Strong Early Responses

Send us Fan Mail A cancer therapy discovered through Australian nature sounds like folklore until you hear the data and the strategy behind it. Andrew is joined by Ebru Davidson, interim CEO and Managing Director of QBiotics Limited, to unpack how an unlisted Brisbane biotech is building “partner-ready” clinical programs from its epoxy tigilianes platform. We walk through tigilanol tiglate (TT), an intratumoural oncology drug candidate in phase two development, and what it means to report a 78% objective response rate in injected tumours in a refractory head and neck cancer trial. Ebru explains the clinical context, why durability matters, and the drug’s multifactorial mechanism of action: rapid tumour destruction, vascular disruption, local inflammation, and immune activation. We also talk about why consistent signals across head and neck cancer and soft tissue sarcoma strengthen the case for tumour-agnostic potential, even while each indication still needs its own evidence path. Then we shift to chronic wounds and EBC-1013, a wound-healing hydrogel in a phase one dose-escalation trial for venous leg ulcers. You’ll hear how the approach differs from standard wound care, why disrupting biofilm and restarting the biology of healing could be critical for hard-to-heal wounds, and what “success” should look like for patients and health systems. We close with near-term milestones, the funding mix across programs, and how QBiotics thinks about partnering, non-dilutive funding, and the road to larger trials and regulators like the FDA and EMA. If you found this useful, subscribe, share it with someone following Australian biotech and clinical trials, and leave a review. What’s the most important proof point you want to see next from TT or EBC-1013?

September 20, 202611 min

ALCHEMY RESOURCES LTD (ASX:ALY) Bryah Basin Iron Ore Breakthrough

Send us Fan Mail ASX Investment Opportunity - Alchemy Resources Ltd (ASX:ALY) A junior explorer can’t do everything at once, so the smart ones pick their shots, partner early, and protect the balance sheet while they drill. That’s what we dig into with James Wilson, CEO of Alchemy Resources Limited, after a busy quarter across Western Australia and New South Wales that moves iron ore, copper-gold and gold assets forward while keeping funding front of mind. We start with the Bryah Basin iron ore project, where Newcam Minerals exercises its option to earn 60% and step into the manager’s seat. James explains why that matters: Newcam brings real iron ore mining experience, integrated haulage and established shipping and sales pathways, while Alchemy is free carried through to a decision to mine. We also unpack what the Valley Bore results suggest about scale and continuity, and what the practical development pathway looks like from flora and fauna studies through to a focused drill-out and the permits needed to prepare for mining. Then we head to Yellow Mountain, Alchemy’s flagship copper-gold and base metals play, where RC drilling is underway against a backdrop of historic mining, surface mineralisation and a standout intercept of 113 metres at 1.17% copper equivalent. James walks us through induced polarisation geophysics, the logic behind chasing a large anomaly under the mountain, and why a potential porphyry source could be the key to a bigger discovery. We also cover the portfolio refocus via the Karonie and Lake Rebecca sale to Forrestania (and the value of NSR royalties), the Billabong Gold JV with Catalyst Metals, and how $800,000 cash plus a liquid share parcel supports near-term drilling without rushing into dilution. If you follow ASX resources, mineral exploration drilling, and the reality of funding high-impact targets, hit play, subscribe, share the episode, and leave a review so more investors can find the show.

September 15, 202611 min

AML3D LTD (ASX:AL3) - Record FY26 Results Show What Scales Next For AML3D

Send us Fan Mail ASX Investment Opportunity - AML3D Ltd (ASX:AL3) A metal part fails on a ship, the clock starts ticking, and the supply chain suddenly matters more than the design. That’s the lens we bring to our chat with Sean Ebert, Managing Director and CEO of AML3D Limited, as we unpack how industrial-scale metal 3D printing is moving into real defence and infrastructure workflows, not just lab demos. We talk through AML3D’s record FY26 result, including $12.5 million in revenue growth and the first half-year EBITDA profit, and what changed operationally to get there. Sean breaks down how the ARCEMY® additive manufacturing system works, why the company sells both systems and printed parts, and how contracted work rolling into FY27 and beyond creates genuine revenue visibility. We also dig into the drivers behind strong gross margins and what “pricing power” looks like when your customers are major industrial and defence organisations. From there, we zoom in on the US Navy scale-up: 14 ARCEMY® systems contracted into the maritime industrial base, a pathway that starts with smaller contractors and moves up to primes like HII and Austal, and a US Navy letter of intent that signals demand out to 2030. Sean also explains the Navy’s “interchangeability” rule and why it could lift adoption of additive manufactured components versus traditional casting and forging. Beyond defence, we explore why Tennessee Valley Authority and other energy-sector wins matter strategically, and what needs to happen before a UK and European footprint becomes more than a plan. If you care about ASX industrial tech, defence supply chains, additive manufacturing, and what can make or break execution at scale, hit play. Subscribe, share the episode with a mate, and leave us a review with your biggest question about where metal 3D printing goes next.

September 13, 202612 min

GALE PACIFIC LTD (ASX:GAP) - GALE Pacific’s Turnaround Playbook

Send us Fan Mail ASX Investment Opportunity - GALE Pacific Ltd (ASX:GAP) Revenue drops, yet EBITDA rises and the balance sheet flips to net cash. That’s the tension at the heart of our chat with Troy Mortleman, CEO of GALE Pacific Limited, the ASX-listed manufacturer behind innovative shade fabrics and technical textile solutions sold across Australia, New Zealand, the United States, Dubai and more than 40 countries. We walk through how GALE Pacific lifts earnings quality on a smaller revenue base by tightening cost control, simplifying operations, and improving product and customer mix. Troy explains the $7m+ operating expense reduction, including the Americas operating model reset, and why protecting customer-facing capability matters when you’re cutting costs. We also unpack the FY26 “mixed result” scorecard: a net loss alongside meaningful progress in cash flow, inventory and financial resilience. The cash flow story is the standout. Operating cash flow swings to $21.4m and the company moves from net debt to net cash, powered by disciplined working capital management and an $8.6m inventory reduction without lowering service levels. From there we go region by region: soft US consumer demand and deliberate retailer inventory realignment, new retail agreements that expand reach to 12,000+ outlets, and a sharp ANZ margin lift driven by mix and cost discipline. Troy also discusses grain storage demand cycles, Middle East disruption risk and the advantage of holding inventory in Dubai, plus momentum in Europe, Asia and India. We finish with the strategic moves investors care about: manufacturing diversification with a trusted partner in Thailand, warehouse consolidation in China, and the key milestones to watch over the next 12 to 18 months. Subscribe, share this with a fellow ASX follower, and leave us a review with the one metric you think best signals a real turnaround.

Is this your show?

Claim this listing to keep it up to date, reach guests who want to pitch you, and manage bookings with Guestify.

Claim this listing

More Business podcasts